Anti-EGFR strategies employ a range of ligands, including monoclonal antibodies such as cetuximab, peptides like GE11 and its analogues, and nucleic acid aptamers, all of which enhance tumor-specific accumulation and internalization of drug-loaded carriers [63, 64]. The gene discussed is EGFR; the disease is neoplasm.